title: Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.
abstract: Adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis. Experience with allo-SCT for ATL appears encouraging but is limited to Japanese series. This retrospective analysis of the EBMT registry revealed 21 HTLV-I seropositive ATL including 7 acute and 12 lymphoma subtypes. Four patients received auto-SCT and rapidly died from ATL. Out of 17 allo-SCT (4 myeloablative, 13 reduced intensity), 6 are still alive (4 were in CR1 at SCT). Eleven patients died within 2 years, eight from relapse/progression and three from transplant toxicity. Six of seven informative patients who lived >12 months had chronic GVHD. Overall these results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients.
authors.affiliation: Medical Center, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: A
authors.initials: A
authors.lastname: Bazarbachi
authors.affiliation: Department of Haematology, Royal Free Hospital, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Cwynarski
authors.affiliation: LWEBMT Paris Office, Hôpital Saint-Antoine, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Boumendil
authors.affiliation: LWEBMT Paris Office, Hôpital Saint-Antoine, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Finel
authors.affiliation: Department of Haematology, Guys and St Thomas' and Kings College Hospitals, London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Fields
authors.affiliation: Department of Haematology, Guys and St Thomas' and Kings College Hospitals, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Raj
authors.affiliation: Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.affiliation: 1] Service d'Hématologie clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France [2] Universite Pierre & Marie Curie, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Haematology Department, Addenbrookes Hospital, Cambridge University, Cambridge, UK.
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.affiliation: Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Dreger
authors.affiliation: 1] Department of Hematology, Hôpital Necker, University of Paris, Paris, France [2] Imagine Institute, INSERM U1163 CNRS ERL 8254, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Hermine
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D015368:Human T-lymphotropic virus 1; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome